| Outcome Measures: |
Primary: Change from baseline in flow mediated dilatation, 4 weeks, up to maximum 5 weeks | Secondary: Rate of change from baseline in nytrotyrosine marker, 4 weeks, up to maximum 5 weeks|Rate of change from baseline in Intercellular Adhesion Molecule-1, 4 weeks, up to maximum 5 weeks|Rate of change from baseline in Interleukin-6, 4 weeks, up to maximum 5 weeks|Rate of change from baseline in C-reactive protein, 4 weeks, up to maximum 5 weeks|Change from baseline in blood pressure (irbesartan/atorvastatin fixed-dose combination group and irbesartan group), 4 weeks, up to maximum 5 weeks|Change from baseline in low density lipoprotein-C (irbesartan/atorvastatin fixed-dose combination group and atorvastatin group), 4 weeks, up to maximum 5 weeks|Change from baseline in total cholesterol (irbesartan/atorvastatin fixed-dose combination group and atorvastatin group), 4 weeks, up to maximum 5 weeks|Change from baseline in high density lipoprotein-C (irbesartan/atorvastatin fixed-dose combination group and atorvastatin group), 4 weeks, up to maximum 5 weeks|Change from baseline in triglycerides (irbesartan/atorvastatin fixed-dose combination group and atorvastatin group), 4 weeks, up to maximum 5 weeks|Change from baseline in apolipoprotein-A1 (irbesartan/atorvastatin fixed-dose combination group and atorvastatin group), 4 weeks, up to maximum 5 weeks|Change from baseline in apolipoprotein-B (irbesartan/atorvastatin fixed-dose combination group and atorvastatin group) - Time Frame: 4 weeks, up to maximum 5 weeks, 4 weeks, up to maximum 5 weeks|Percentage of participants with decreased level of blood pressure (irbesartan/atorvastatin fixed-dose combination group and irbesartan group), 4 weeks, up to maximum 5 weeks|Rate of change from baseline in immunosenescence T cell fractionation, 4 weeks, up to maximum 5 weeks|Rate of change from baseline in T-cell induced inflammatory factors, 4 weeks, up to maximum 5 weeks
|
